Circulating microRNAs to choose the IO strategy in PD-L1 ≥50% NSCLC patients: the Ark clinical trial
Ente Finanziatore: Bando per la Ricerca Istituzionale
Principal Investigator: Dott.ssa Proto Claudia
Co Principal Investigator: Dott. Boeri Mattia
Data di inizio:
Data di fine:
Struttura Principale: Circulating microRNAs to choose the IO strategy in PD-L1 ≥50% NSCLC patients: the Ark clinical trial
The primary objective of this study is to compare the effectiveness of chemo-immunotherapy versus immunotherapy alone as a first-line treatment in patients with advanced NSCLC and PD-L1 expression ≥50%, who are characterized by the presence of a high-risk circulating MSC biomarker.
Principal Investigator Dr. Proto Claudia
Co Principal Investigator Dott. Boeri Mattia
Molecular Immunology
Research Area, Complex Structure
Epigenomics and Biomarkers of Solid Tumors
Research Area, Complex Structure
Last update: 26/05/2025